BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33739633)

  • 1. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates.
    Jeon SK; Lee JM; Joo I; Yoo J; Park JY
    Eur Radiol; 2020 Sep; 30(9):4762-4771. PubMed ID: 32333148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients.
    Park SH; Shim YS; Kim B; Kim SY; Kim YS; Huh J; Park JH; Kim KW; Lee SS
    Eur Radiol; 2021 Jul; 31(7):4751-4763. PubMed ID: 33389037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies.
    Shin J; Lee S; Yoon JK; Son WJ; Roh YH; Chung YE; Choi JY; Park MS
    Gut Liver; 2023 May; 17(3):466-474. PubMed ID: 36317516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Four Diagnostic Guidelines for Hepatocellular Carcinoma Using Gadoxetic Acid-enhanced Liver MRI.
    Yoon JH; Kim YK; Kim JW; Chang W; Choi JI; Park BJ; Choi JY; Kim SS; Park HS; Lee ES; Yu JS; Park SJ; You MW; Lee CH; Lee JM
    Radiology; 2024 Apr; 311(1):e233114. PubMed ID: 38563667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
    Byun J; Choi SH; Byun JH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Hepatol Int; 2020 Jul; 14(4):534-543. PubMed ID: 32314171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
    Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
    Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
    Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 12. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
    Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
    Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
    Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
    Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
    Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
    Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
    Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria.
    Yoon JK; Lee S; Hwang JA; Lee JE; Kim SS; Kim MJ
    J Liver Cancer; 2023 Mar; 23(1):157-165. PubMed ID: 37384026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.